Precision medicine starts here

Blue Latitude Health|18th May 2018

Precision medicine is set to revolutionise the healthcare sector, promising vastly improved outcomes for patients. However, as treatments become more precise, pharma companies will need to create more targeted commercial strategies. Meanwhile, the clinical trial recruitment process will become more challenging and a new series of stakeholders will emerge. These are just some of the barriers.

That’s why have dedicated the latest edition of our ‘Perspective’ magazine to this complex topic. We have combined the views of our in-house precision medicine experts and voices from key industry leaders to give you the latest information on the trend set to redefine healthcare as we know it – precision medicine.

In this edition of ‘Perspective’, we answer the following questions:

  • Are we ready for precision medicine?
  • How can you master the precision medicine opportunity?
  • How can industry drive greater engagement in the clinical trial recruitment process?
  • Will precision medicine change the way we interact with patients?
  • Who are the new healthcare influencers?

Empowered patients: shaking the foundations of healthcare

Blue Latitude Health|16th August 2019

Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to make a more accurate treatment decision. Here we discuss the barriers, opportunities and potential outcomes of the precision medicine era in healthcare.

read more

A uniquely English genomic medicine service

Natasha Cowan|26th July 2019

The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist and Director of Public Health at Genomics England, to find out how the NHS is achieving this goal.

read more

Diagnosing the lag in neuropsychiatric treatments

Sana Rahim|16th July 2019

The number of mental health research programmes in larger drug firms has shrunk by 70% in the past decade. Blue Latitude Health Senior Associate Consultant Sana Rahim explores this drop in investment and explains why developing a market-orientated model is vital for making progress.

 

read more